Clinical Trials | October 23, 2025
Pimicotinib delivers lasting tumor responses and sustained symptom relief in TGCT patients
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder
These findings follow positive Phase 3 results presented earlier this year
Several technologies for hemoglobinopathies are being transferred to commercial partners
Through this acquisition Merck has added Ohtuvayre (ensifentrine) to its growing cardio-pulmonary pipeline and portfolio
New offering to debut at the 32nd ESGCT Congress, October 7–10, 2025, in Seville, Spain
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment
Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting
The new site enables end-to-end production of viral vector gene therapies
Subscribe To Our Newsletter & Stay Updated
